WallStSmart

ResMed Inc (RMD)vsSpace Exploration Technologies Corp. Class A Common Stock (SPCX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Space Exploration Technologies Corp. Class A Common Stock generates 249% more annual revenue ($19.30B vs $5.54B). RMD leads profitability with a 27.4% profit margin vs -45.0%. RMD earns a higher WallStSmart Score of 73/100 (B).

RMD

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 9.0Value: 4.7Quality: 9.5
Piotroski: 6/9Altman Z: 4.34

SPCX

Avoid

23

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: 0.17
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDSignificantly Overvalued (-26.9%)

Margin of Safety

-26.9%

Fair Value

$204.63

Current Price

$196.04

$8.59 premium

UndervaluedFair: $204.63Overvalued

Intrinsic value data unavailable for SPCX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD5 strengths · Avg: 9.4/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.4%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

SPCX2 strengths · Avg: 9.0/10
Market CapQuality
$1.77T10/10

Mega-cap, among the largest globally

Revenue GrowthGrowth
15.4%8/10

15.4% revenue growth

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

SPCX4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
27.0x2/10

Trading at 27.0x book value

Return on EquityProfitability
-11.9%2/10

ROE of -11.9% — below average capital efficiency

Free Cash FlowQuality
$-9.06B2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bull Case : SPCX

The strongest argument for SPCX centers on Market Cap, Revenue Growth. Revenue growth of 15.4% demonstrates continued momentum.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : SPCX

The primary concerns for SPCX are EPS Growth, Price/Book, Return on Equity.

Key Dynamics to Monitor

RMD profiles as a mature stock while SPCX is a growth play — different risk/reward profiles.

SPCX is growing revenue faster at 15.4% — sustainability is the question.

RMD generates stronger free cash flow (520M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RMD scores higher overall (73/100 vs 23/100), backed by strong 27.4% margins and 10.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Space Exploration Technologies Corp. Class A Common Stock

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Space Exploration Technologies Corp. The company is headquartered in Starbase, Texas.

Want to dig deeper into these stocks?